A tool-based approach can significantly aid in the harmonization of regulatory requirements, mitigate inadvertent risks, and ...
In this video interview, Vera Pomerantseva, director of product management, RBQM, eClinical Solutions, talks FDA’s latest protocol deviation guidance and potential changes to the draft.
Policy change by the Trump administration now allows the agency to post public notices in the Federal Register and advertise ...
Phase III PRESTIGE-AF trial shows that direct oral anticoagulants significantly lower the risk of ischemic stroke in ...
Discover how evolving clinical trial trends are reshaping patient and site experiences—and the steps sponsors can take to stay ahead—in this conversation with uMotif CEO Steve Rosenberg at SCOPE ...
External control arms, as an integral part of clinical development, present many potential opportunities for sponsors and ...
In this video interview, Vera Pomerantseva, director of product management, RBQM, eClinical Solutions, highlights FDA’s ...
Following initial positive results shared by Teva and Sanofi in December 2024, new data shows duvakitug (TEV’574/SAR447189) ...
In this video interview, Pomerantseva, director of product management, RBQM, eClinical Solutions, discusses the new guidance and its level of detail on the different types of protocol deviations.
In an interview with Applied Clinical Trials Associate Editor Don Tracy, Shakthi Kumar, chief strategy & business officer, ...
In this video interview, Dipanwita Das, CEO & co-founder, Sorcero; Sujay Jadhav, CEO, Verana Health; and Kimberly Tableman, ...
Symbravo Outperforms Oral CGRP Inhibitors in Phase III Trial, With Faster, Sustained Migraine Relief
Data from the Phase III EMERGE trial show treatment with Symbravo provided more rapid and sustained migraine relief with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback